KAI Pharmaceuticals Initiates Phase 2b Clinical Study of KAI-9803 in Heart Attack Patients

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced today the enrollment of the first... [more]

View complete Press Release article